Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Completed · Phase 1
Conditions studied: Progressive Metastatic Malignancies
In brief
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic profile of ALT-801 in previously treated patients with progressive metastatic malignancies. ALT-801, a recombinant fusion protein with a interleukin-2 (IL-2) component, has a targeting mechanism that recognizes tumor cells with a specific tumor marker.
Key facts
- Study ID
- NCT00496860
- Run by
- Altor BioScience
- People needed
- 26
- Starts
- 2007-05-01
- Expected to finish
- 2009-10-01
- Last updated by the study team
- 2013-07-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Colorado, Anschutz Cancer Pavillion — Aurora, Colorado, United States
- MD Anderson Cancer Center Orlando — Orlando, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
- University of Washington, Seattle Cancer Care Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.